Franklin Strategic Series · net assets $1.15B · 126 holdings as of July 31, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 93.9% · STIV: 4.5% · EP: 1.0% · OTHER: 0.6%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $10.3M | $12.9M | $22.9M |
| Reinvestment | $0 | $0 | $0.23 |
| Redemptions | $17.4M | $15.5M | $16.8M |
| Net realized gain (non-derivative) | $-2.44M | $28.6M | $25.2M |
| Net unrealized appreciation (non-derivative) | $35.1M | $85.3M | $-48.7M |
The three months of the reporting period, as filed; month 3 ends July 31, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Jazz Pharmaceuticals PLC EC | $65.3M | 5.66% |
| Amgen, Inc. EC | $50.7M | 4.39% |
| Gilead Sciences, Inc. EC | $44.5M | 3.86% |
| Regeneron Pharmaceuticals, Inc. EC | $43.5M | 3.77% |
| Argenx Se EC | $41.8M | 3.62% |
| Vertex Pharmaceuticals, Inc. EC | $40.8M | 3.54% |
| Franklin Institutional U.s. Government Money Market Fund STIV | $36.7M | 3.18% |
| Revolution Medicines, Inc. EC | $34.8M | 3.01% |
| Guardant Health, Inc. EC | $31.8M | 2.76% |
| Ascendis Pharma A/s EC | $29.6M | 2.56% |
| Dianthus Therapeutics, Inc. EC | $26.8M | 2.32% |
| Insmed, Inc. EC | $23M | 1.99% |
| Mirum Pharmaceuticals, Inc. EC | $22.8M | 1.98% |
| Praxis Precision Medicines, Inc. EC | $22.1M | 1.91% |
| Spyre Therapeutics, Inc. EC | $21.6M | 1.87% |
| Oruka Therapeutics, Inc. EC | $21.5M | 1.86% |
| Neurocrine Biosciences, Inc. EC | $21M | 1.82% |
| Bridgebio Pharma, Inc. EC | $19.3M | 1.67% |
| Ptc Therapeutics, Inc. EC | $19M | 1.65% |
| Astrazeneca PLC EC | $17.4M | 1.51% |
| Franklin Institutional U.s. Government Money Market Fund STIV | $16.7M | 1.45% |
| Amylyx Pharmaceuticals, Inc. EC | $15.3M | 1.32% |
| Eli Lilly & Co. EC | $15.1M | 1.31% |
| Cytokinetics, Inc. EC | $14.3M | 1.24% |
| Tango Therapeutics, Inc. EC | $14.2M | 1.23% |
| Eyepoint, Inc. EC | $13.8M | 1.19% |
| Abivax Sa EC | $13.6M | 1.18% |
| Mineralys Therapeutics, Inc. EC | $13.6M | 1.18% |
| Arcutis Biotherapeutics, Inc. EC | $13.6M | 1.18% |
| Indivior Pharmaceuticals, Inc. EC | $13.3M | 1.15% |
| Thermo Fisher Scientific, Inc. EC | $13.2M | 1.14% |
| Dyne Therapeutics, Inc. EC | $13.1M | 1.13% |
| Bicara Therapeutics, Inc. EC | $12.9M | 1.11% |
| Cg Oncology, Inc. EC | $12.4M | 1.08% |
| Benitec Biopharma, Inc. EC | $11.7M | 1.01% |
| Alkermes PLC EC | $11.4M | 0.99% |
| Solid Biosciences, Inc. EC | $11.4M | 0.98% |
| Syndax Pharmaceuticals, Inc. EC | $11.1M | 0.96% |
| Ionis Pharmaceuticals, Inc. EC | $10.8M | 0.94% |
| Beone Medicines Ltd. EC | $10.6M | 0.92% |
| Alnylam Pharmaceuticals, Inc. EC | $10.5M | 0.91% |
| Jade Biosciences, Inc. EC | $9.48M | 0.82% |
| Vaxcyte, Inc. EC | $7.88M | 0.68% |
| Xenon Pharmaceuticals, Inc. EC | $7.76M | 0.67% |
| Relay Therapeutics, Inc. EC | $7.63M | 0.66% |
| Oric Pharmaceuticals, Inc. EC | $7.3M | 0.63% |
| Neurogene, Inc. EC | $7.2M | 0.62% |
| Oruka Therapeutics, Inc. EC | $7.13M | 0.62% |
| Achieve Life Sciences, Inc. EC | $7.03M | 0.61% |
| Biontech Se EC | $6.65M | 0.58% |
| Olema Pharmaceuticals, Inc. EC | $6.51M | 0.56% |
| Obsidian Therapeutics, Inc. EC | $6.39M | 0.55% |
| Mbx Biosciences, Inc. EC | $5.64M | 0.49% |
| Candid, Inc. EC | $5.56M | 0.48% |
| Processa Pharmaceuticals, Inc. EP | $5.51M | 0.48% |
| Artiva Biotherapeutics, Inc. EC | $5.48M | 0.47% |
| Aura Biosciences, Inc. EC | $5.37M | 0.46% |
| Newamsterdam Pharma Co. Nv EC | $5.22M | 0.45% |
| Contineum Therapeutics, Inc. EC | $5.11M | 0.44% |
| Sionna Therapeutics, Inc. EC | $5.09M | 0.44% |
Showing top 60 of 126 holdings.
Loading...
